Just received tha Annual Meeting info.
One of the items to vote on is a reverse split in the range of 1 for 5 to 1 for 25...as determined by the baord of Directors...
And so it begins to avoid delisting.....
MANATEE COUNTY - It was almost a year ago that the company now known as Rock Creek Pharmaceuticals was moved from Virginia to the Roskamp Institute campus here. At the same time, it changed from selling an over-the-counter neutraceutical that helped people quit smoking to a prescription pharmaceutical developer.
It has been a rough year, based on the company's annual report to the U.S. Securities and Exchange Commission and an interview with CEO Michael Mullan.
Last year, the company closed three offices: Washington D.C.; Glen Allen, Virginia; and Gloucester, Massachusetts. It also laid off two-thirds of its workers and incurred lawsuits.
The company reported a loss of $38.5 million for 2014, even more than the $32.8 million of 2013, when it was still known as Star Scientific.
As a marketing company, Star Scientific had cash flow from over-the-counter sales of two anatabine citrate-based products, trademarked as "Anatabloc" and "CigRx."
When the company began its transition, Rock Creek's team thought they could keep selling the over-the-counter neutraceutical while developing anatabine's résumé as a prescription product.
Change of plans
But the Food and Drug Administration thought otherwise. So in August, with an FDA action coming, Rock Creek voluntarily stopped selling Anatabloc and CigRx.
At roughly the same time, Mullan left his role as Roskamp's CEO in order to run Rock Creek.
"The downsizing is consistent with what the company is now," Mullan said. "It is a pharmaceutical-development company and is moving the compound through clinical trials. For that, you don't need a big staff."
The payroll, which was 28 going into the move, is now nine.
~ck (R/S. coming to stay listed)
And now the vulture lawyers are hovering over ACAD. big surprise.
Having seen the effects of Parkinson on patients and families, I hope there isn't more to this story as far as the delay.
CEO resigns the same day as the postponement seems strange. I'm not sure i am buying the "manufacturing" story.
I am looking for an entry point but will wait..not sure what will happen tomorrow morning.
~ck (Kerx looking safe right now)
In wake of the acquisition of of Cubist Pharmaceuticals, Watertown biotech firm Tetraphase Pharmaceuticals has become the area's leading developer of antibiotics, and now it's looking to double its cash on hand through a stock offering.
Tetraphase (Nasdaq: TTPH) shares were down about 4 percent as of 1:30 p.m. today after announcing plans to sell 3.4 million shares. At its current stock price of $34.60, that would raise $118 million on top of the $121 million in said it had as of Dec. 31 in its most recent financial update.
The company aims to submit its potential new antibiotic, called eravacycline, for approval in the U.S. later this year, pending the results of the second of two late-stage trials to be announcing in coming months. If approved, it would be the first for the biotech.
The company's success in bringing eravacycline to approval has resulted in speculation that it, too, could be acquired soon. Likely suitors have been named as Swiss drug giants Roche or Actelion Pharmaceuticals, New York-based Pfizer or New Jersey-based The Medicines Company. If it does eventually get purchased, it would be the second local antibiotics firm to be bought after Merck & Co. paid $9.5 billion for Cubist in a deal completed in January.
Here are the after hours trades: yes..it is there:
After Hours Time (ET) After Hours Price After Hours Share Volume
16:25 $ 23.38 Low 2,358
16:00 $ 23.7282 High 9,230
16:00 $ 23.7282 High 169
16:00 $ 23.38 100
16:00 $ 23.38 9,405
~ck (new investor in EXAS)
Keryx Biopharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of Nephrology
Date(s): 4-Mar-2015 7:45 AM
For a complete listing of our news releases, please click here
~ck (very long)
Sentiment: Strong Buy
I am still holding my shares even though they have tanked..
Anyone else here?
Sentiment: Strong Buy
Keryx Biopharmaceuticals, Inc. has posted a new presentation to its Investor Relations website.
Title: Cowen and Company 35th Annual Health Care Conference Presentation
Date(s): Mar 02 2015
I have been invested in KERX for a very long time and still own most of my position.
I was underwater for years when the stock was in the tank. I am sure many can remember.
I have been a subscriber to the WSJ for most of my adult life. I was not happy about the article, but to say it was a plant or they stooped too low is not a fair statement. The fact is, the launch has been disappointing as the PPS shows...and yes, it is early in the game.
I am hoping for the best over the longer term, but I have been to this rodeo before. Perhaps Ron and the BOD should have partnered or sold to a larger more established pharma. Time will tell.
I am not selling at this point.
Here are the trades in HART during the regular session on Friday:
This is a very thinly traded stock, so it doesn't take much to swing the pps.
You obviously know nothing about this company.
Construction is booming here in FL..In addition, many insurance companies are now requiring windows in existing homes to meet current hurricane code.
I bought more shares to average down today.
Although they are debt heavy, there is a good chaance for a rebound in oil later this year.
08:30 $ 12.29 200
08:24 $ 12.33 1,000
08:22 $ 12.35 High 5
08:22 $ 12.35 High 900
08:22 $ 12.25 5
08:22 $ 11.95 281
08:20 $ 12.07 5
08:20 $ 12.25 1,000
08:16 $ 11.94 Low 300
08:16 $ 11.94 Low 100
08:10 $ 11.96 100
08:06 $ 11.94 200
Here is what he said:
"I am very pleased to report that the U.S. launch of Auryxia is progressing as planned, with a good reception to date from both payers and providers," said Greg Madison, President and Chief Operating Officer. "We are well on our way to achieving the goal of broad unrestricted access for Part D and commercial payers within several months."
Yes...they had $85M in cash at YE and after expenses another $110K from the 2015 offering...less what they have spent in Jan/Feb.
As i said, wait for the CC at 8AM before listiening to MBs.